Tomorrow due a $.30 pop, if their pattern continues - - not much point in trying to fit a fundamental or technical explanation to this; we all know what they're doing. So far, the analsysts not backing off much; that's something to hold on to.
On these levels cris is a strong buy! And we all can do that. I do not expect management to buy, they have their own options. I am sure we will get some positive news soon, management does not need to make up them. Hedgehog inhibition is will demonstrate it's power in many different cancers but the big thing is the the multi-head molecules which will be a part of almost every cancer treatment in future. Just buy and buy!! It will be rewarded IMO!! But do your own research!!
You may count yourself as one more baffled investor here on the CRIS board. That very topic has been the subject of numerous posts here.
Some of the facts we do know: 1. Short interest is up 2.5M shares (about 50%) since January 30th, the time of Erivedge approval 2. Aside from positive pancreatic news in June, no major NCI trial results have been unveiled 3. Larger news like European approval for Erivedge or filing of an IND for the oral formulation of CUDC-101 has not occurred yet in 2012 4. No insider buying from management 5. No notable, consistent PR from the company on all of the potential here
I'm usually not openly critical of the company, since I feel that the CEO and the management team has done a good job guiding the development processes of their assets and managing their finances. And although there is nothing that can be done about the first 3 reasons above, there is certainly something that can be done about the last 2.